MK-2206
Drug timelines are a Plus or Pro feature.
40 regulatory and trial events tracked for MK-2206, covering 2013-05-03 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer [Phase 1]